Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia

AIDS Research and Human Retroviruses

Volumn 18, Issue 14, 2002, Pages 1011-1019

  Paulsen, Denise ^a   Liao, Qiming ^a   Fusco, Gregory ^a   St Clair, Marty ^a   Shaefer, Mark ^a   Ross, Lisa ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS RESISTANCE; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION;

CARBAMATES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; PYRIMIDINONES; RETROSPECTIVE STUDIES; RNA, VIRAL; SULFONAMIDES; VIREMIA;

EID: 0036387141     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220260235371     Document Type: Article

References (22)

1. Mocroft A, Vella S, Benfield T, et al.: Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-1730.
2. Palella F Jr, Delaney K, Moorman A, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853 -860.
3. Arici C, Ripamonti D, Ravasio V, et al.: Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution. Int J STD AIDS 2001;12:573 -581.
4. Antionori A, Cingolani A, Alba L, et al.: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15: 1483-1491.
5. Murphy E, Collier A, Kalish L, et al.: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
6. Skiest D, Chiller T, Chiller K, Park A, and Keiser P: Protease inhibitor therapy is associated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis. Int J STD AIDS 2001;12:659-664.
7. Besson C, Goubar A, Gabarre J, et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344.
8. Sendi P, Palmer A, Gafni A, and Battegay M: Highly active antiretroviral therapy: Pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 2001;19:709 -713.
9. Zaidi I, Weinstock H, Woods T, Thomas J, Heneine W, and Kaplan J: Prevalence of mutations associated with antiretroviral drug resistance among HIV-1-infected persons in 10 US cities, 1997-2000 [abstract]. Antiviral Ther 2001;6(Suppl 1):118.
10. Little S, Holte S, Routy J, et al.: Antiretroviral resistance and response to initial therapy among recently HIV-infected subjects in North America [abstract]. Antiviral Ther 2001;6(Suppl 1):21.
11. Hirsch M, Brun-Vezinet F, D'Aquila R, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000;283: 2417-2426.
12. Panel IAS-URTG. Update on drug resistance mutations in HIV-1. Top HIV Med 2001;9:31-33.
13. Yu K and Daar E: Dual protease inhibitor therapy in the management of HIV-1 [review]. Expert Opin Pharmacother 2000;1:1331-1342.
14. Noble S and Goa K: Amprenavir: A review of its clinical potential in patients with HIV infection. Drugs 2000;60:1383-1410.
15. Sale M, Sadler B, and Stein D: Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002;46:746-754.
16. Ross L, Scarsella A, Raffanti S, et al.: Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses 2001;17: 1107-1115.
17. Kempf D, Isaacson J, King M, et al.: Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001;75:7462 -7469.
18. Maguire M, Shortino D, Klein A, et al.: Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002;46:731-738.
19. Tisdale M, Myers R, Maschera B, Parry N, Oliver N, and Blair E: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39: 1704-1710.
20. Schmidt B, Korn K, Moschik B, Paatz C, Uberla K, and Walter H: Low level of cross-resistance to amprevanir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother 2000;44:3213 -3216.
21. Elston R, Wolfram J, Richards N, Tisdale M, Klein J, and Snowden W: Differential impact of specific key mutations in HIV protease on phenotypic susceptibility to amprenavir and lopinavir [abstract]. Antiviral Ther 2001;6(Suppl 1):53-54.
22. Tisdale M, Myers R, Randall S, et al.: Evolution of resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies [review]. Clin Drug Invest 2000;20:267-285.